2013-09-10 10:56:12 - Fast Market Research recommends "Ulcerative Colitis - Pipeline Review, H2 2013" from Global Markets Direct, now available
Global Markets Direct's, 'Ulcerative Colitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ulcerative Colitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ulcerative Colitis. Ulcerative Colitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
Full Report Details at
- www.fastmr.com/prod/675193_ulcerative_colitis_pipeline_review_h2 ..
* A snapshot of the global therapeutic scenario for Ulcerative Colitis.
* A review of the Ulcerative Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Ulcerative Colitis pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.
Reasons to Get this Report
* Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Companies Mentioned in this Report: Bristol-Myers Squibb Company, Johnson & Johnson, Amgen Inc., Sanofi-Aventis, AstraZeneca PLC, Athersys, Inc., GlaxoSmithKline plc, Genentech, Inc., MedImmune LLC, Gilead Sciences, Inc., Euroscreen S.A., Takeda Pharmaceutical Company Limited, BioLineRx, Ltd., Celltrion, Inc., Sylentis, Axcan Pharma Inc., Biocon Limited, Pfizer Inc., Sigma-Tau S.p.A., 4SC AG, GW Pharmaceuticals plc, Hollis-Eden Pharmaceuticals, Inc., iCo Therapeutics Inc., Karo Bio, Ore Pharmaceuticals Inc, Cosmo Pharmaceuticals S.p.A, Lexicon Pharmaceuticals, Inc., LTT Bio-Pharma Co., Ltd., Galapagos NV, InDex Pharmaceuticals AB, Am-Pharma B.V., Upsher-Smith Laboratories, Inc., Palau Pharma S.A, Farmacija d.o.o. Tuzla, Hutchison MediPharma Limited, Viropro Inc., Tillotts Pharma AG, Coronado Biosciences, Inc., Amalyte Pharmaceuticals, LLC, GP Pharm, S.A., Vascular Biogenics Ltd., TcL Pharma SAS, Avaxia Biologics, Inc., Drais Pharmaceuticals, Inc., Giuliani S.p.A., Synergy Pharmaceuticals, Inc., Medestea Research & Production S.p.A., NasVax Ltd., Antibe Therapeutics, Inc., Dr. Falk Pharma GmbH, Flexion Therapeutics, Receptos, Inc., Altheus Therapeutics, Inc., AesRx, LLC., LIPID THERAPEUTICS GmbH, Atlantic Healthcare Limited, Sigmoid Pharma., Advancell
Partial Table of Contents:
Table of Contents
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
Ulcerative Colitis Overview
An Overview of Pipeline Products for Ulcerative Colitis
Ulcerative Colitis Therapeutics under Development by Companies
Ulcerative Colitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Discovery and Pre-Clinical Stage Products
Ulcerative Colitis Therapeutics - Products under Development by Companies
Ulcerative Colitis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Ulcerative Colitis Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Gilead Sciences, Inc.
Takeda Pharmaceutical Company Limited
Axcan Pharma Inc.
GW Pharmaceuticals plc
Hollis-Eden Pharmaceuticals, Inc.
iCo Therapeutics Inc.
Ore Pharmaceuticals Inc
Cosmo Pharmaceuticals S.p.A
Lexicon Pharmaceuticals, Inc.
LTT Bio-Pharma Co., Ltd.
InDex Pharmaceuticals AB
Upsher-Smith Laboratories, Inc.
Palau Pharma S.A
Farmacija d.o.o. Tuzla
Hutchison MediPharma Limited
Tillotts Pharma AG
Coronado Biosciences, Inc.
Amalyte Pharmaceuticals, LLC
GP Pharm, S.A.
Vascular Biogenics Ltd.
TcL Pharma SAS
Avaxia Biologics, Inc.
Drais Pharmaceuticals, Inc.
Synergy Pharmaceuticals, Inc.
Medestea Research & Production S.p.A.
Antibe Therapeutics, Inc.
Dr. Falk Pharma GmbH
Altheus Therapeutics, Inc.
LIPID THERAPEUTICS GmbH
Atlantic Healthcare Limited
Ulcerative Colitis - Therapeutics Assessment
Assessment by Monotherapy Products
Full Table of Contents is available at:
About Global Markets Direct
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.